Big Bull
2021-11-18
Good
Cassava Sciences Stock Tumbles on News of SEC Investigation
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":878532155,"tweetId":"878532155","gmtCreate":1637204802922,"gmtModify":1637204802922,"author":{"id":4094912318336650,"idStr":"4094912318336650","authorId":4094912318336650,"authorIdStr":"4094912318336650","name":"Big Bull","avatar":"https://static.tigerbbs.com/a882f1e1fca8900b7ba0fae0ed568a02","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":12,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good </p></body></html>","htmlText":"<html><head></head><body><p>Good </p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/878532155","repostId":1161909759,"repostType":4,"repost":{"id":"1161909759","kind":"news","pubTimestamp":1637203262,"share":"https://www.laohu8.com/m/news/1161909759?lang=&edition=full","pubTime":"2021-11-18 10:41","market":"us","language":"en","title":"Cassava Sciences Stock Tumbles on News of SEC Investigation","url":"https://stock-news.laohu8.com/highlight/detail?id=1161909759","media":"The Street","summary":"The biotech faces claims of manipulating research results of its Alzheimer’s drug.\n$Cassava Sciences","content":"<p>The biotech faces claims of manipulating research results of its Alzheimer’s drug.</p>\n<p>$Cassava Sciences (<b>SAVA</b>)$ plummeted Wednesday after disclosing that \"certain government agencies\", which reportedly included the Securities and Exchange Commission, were investing claims the biotech manipulated research results of its experimental Alzheimer’s drug, simufilam.</p>\n<p>Shares of the Austin, Texas company were down more than 23% to $47.07 Wednesday.</p>\n<p><img src=\"https://static.tigerbbs.com/ba12f81714da2c89bed996a8439c131d\" tg-width=\"882\" tg-height=\"624\" referrerpolicy=\"no-referrer\"></p>\n<p>Cassava said in a securities filing that \"certain government agencies have asked us to provide them with corporate information and documents\" and the Wall Street Journal, citing people familiar with the matter, that the agency was the SEC.</p>\n<p>\"We have been cooperating and will continue to cooperate with government authorities,\" Cassava said it is filing. \"No government agency has informed us that any wrongdoing has occurred by any party.\"</p>\n<p>The National Institutes of Health, which awarded $20 million in grants to Cassava and its academic collaborators since 2015 for drug development, is also examining the claims, according to the company’s chief executive officer.</p>\n<p>Cassava Sciences becameembroiled in controversyin August when Jordan Thomas, a partner and chair of the whistleblower representation practice at Labaton Sucharow, filed a citizen's petition with the U.S. Food and Drug Administration seeking to halt to trials of simufilam.</p>\n<p>On Wednesday, Thomas wrote a letter to acting U.S. Food and Drug Administration Janet Woodcock saying \"my clients’ worst fears about Cassava Sciences appear to have been true.\"</p>\n<p>Thomas identified his clients as David Bredt, former neuroscience research chief at Johnson & Johnson (<b>JNJ</b>) Report and Eli Lilly & Co. (<b>LLY</b>) , and Geoffrey Pitt, a cardiologist and professor at Weill Cornell Medicine</p>\n<p>\"Due to their serious concerns about simufilam and related research by Cassava,\" Thomas said, \"and at great personal and professional risk, my whistleblower clients, along with other prominent doctors and scientists, have voluntarily gone on the record.\"</p>\n<p>Bredt and Pitt wrote that Cassava’s research include images of experiments that appear to have been manipulated using software such as Photoshop.</p>\n<p>Thomas said that \"increasingly evidence suggests that Cassava has doctored its research and clinical trial results, duped peer-reviewed journals, used the tainted science to trick the NIH and FDA into approving grants and clinical trials.\"</p>\n<p>In addition, the company \"misled investors by touting their grants and clinical trials without disclosing their troubling research practices, and withheld material information about the true nature of its drug from vulnerable Alzheimer’s Disease patients.\"</p>\n<p>The FDA has a duty, Thomas said, \"to immediately halt the simufilam clinical trials, conduct a rigorous audit of all the company’s research and clinical trial results, and report the agency’s findings to interested law enforcement and regulatory authorities.\"</p>\n<p>Cassava did not immediately respond to a request for comment, but Chief Executive Remi Barbier has said that short sellers have abused the FDA’s petition process.</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cassava Sciences Stock Tumbles on News of SEC Investigation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCassava Sciences Stock Tumbles on News of SEC Investigation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-18 10:41 GMT+8 <a href=https://www.thestreet.com/investing/cassava-sciences-stock-tumbles-on-news-of-sec-investigation><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech faces claims of manipulating research results of its Alzheimer’s drug.\n$Cassava Sciences (SAVA)$ plummeted Wednesday after disclosing that \"certain government agencies\", which reportedly ...</p>\n\n<a href=\"https://www.thestreet.com/investing/cassava-sciences-stock-tumbles-on-news-of-sec-investigation\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SAVA":"Cassava Sciences Inc"},"source_url":"https://www.thestreet.com/investing/cassava-sciences-stock-tumbles-on-news-of-sec-investigation","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161909759","content_text":"The biotech faces claims of manipulating research results of its Alzheimer’s drug.\n$Cassava Sciences (SAVA)$ plummeted Wednesday after disclosing that \"certain government agencies\", which reportedly included the Securities and Exchange Commission, were investing claims the biotech manipulated research results of its experimental Alzheimer’s drug, simufilam.\nShares of the Austin, Texas company were down more than 23% to $47.07 Wednesday.\n\nCassava said in a securities filing that \"certain government agencies have asked us to provide them with corporate information and documents\" and the Wall Street Journal, citing people familiar with the matter, that the agency was the SEC.\n\"We have been cooperating and will continue to cooperate with government authorities,\" Cassava said it is filing. \"No government agency has informed us that any wrongdoing has occurred by any party.\"\nThe National Institutes of Health, which awarded $20 million in grants to Cassava and its academic collaborators since 2015 for drug development, is also examining the claims, according to the company’s chief executive officer.\nCassava Sciences becameembroiled in controversyin August when Jordan Thomas, a partner and chair of the whistleblower representation practice at Labaton Sucharow, filed a citizen's petition with the U.S. Food and Drug Administration seeking to halt to trials of simufilam.\nOn Wednesday, Thomas wrote a letter to acting U.S. Food and Drug Administration Janet Woodcock saying \"my clients’ worst fears about Cassava Sciences appear to have been true.\"\nThomas identified his clients as David Bredt, former neuroscience research chief at Johnson & Johnson (JNJ) Report and Eli Lilly & Co. (LLY) , and Geoffrey Pitt, a cardiologist and professor at Weill Cornell Medicine\n\"Due to their serious concerns about simufilam and related research by Cassava,\" Thomas said, \"and at great personal and professional risk, my whistleblower clients, along with other prominent doctors and scientists, have voluntarily gone on the record.\"\nBredt and Pitt wrote that Cassava’s research include images of experiments that appear to have been manipulated using software such as Photoshop.\nThomas said that \"increasingly evidence suggests that Cassava has doctored its research and clinical trial results, duped peer-reviewed journals, used the tainted science to trick the NIH and FDA into approving grants and clinical trials.\"\nIn addition, the company \"misled investors by touting their grants and clinical trials without disclosing their troubling research practices, and withheld material information about the true nature of its drug from vulnerable Alzheimer’s Disease patients.\"\nThe FDA has a duty, Thomas said, \"to immediately halt the simufilam clinical trials, conduct a rigorous audit of all the company’s research and clinical trial results, and report the agency’s findings to interested law enforcement and regulatory authorities.\"\nCassava did not immediately respond to a request for comment, but Chief Executive Remi Barbier has said that short sellers have abused the FDA’s petition process.","news_type":1},"isVote":1,"tweetType":1,"viewCount":291,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/878532155"}
精彩评论